Indeed, we previously showed that the anti-tumor activity of combined GARP:TGF-β1/PD-1 blockade was lost in Treg-specific Garp knock-out mice bearing MC38 tumors, suggesting that targeting GARP-expressing Tregs is indispensable for anti-GARP:TGF-β1 to exert anti-tumor activity (8). This evidence concerns the gene TGFB1 and neoplasm.